Study | Country | Method | Prostate cancer | Prostate non cancer controls | P value |
---|---|---|---|---|---|
Sutcliffe 2006 [86] | US | Serology | 87/691 13% | 65/691 9% | 0.090Â ns |
Sutcliffe 2009 [114] | US | Serology | 132/616 22% | 153/616 25% | 0.262 ns Control > cancer |
Stark 2009 [115] | US | Serology | 165/673 25% | 144/673 21% | 0.402Â ns |
Chen 2013 [116] | US | Serology | 87/603 14% | 65/627 10% | 0.056Â ns |
Shui 2016 [117] | US | Serology | 24/122 20% | 42/139 30% | 0.130 ns Control > cancer |
Fowke 2016 [118] | US | Serology | 69/296 23% | 124/585 21% | 0.567Â ns |
Marous 2017 [119] | US whites US blacks | Serology | 84/777 11% 43/158 27% | 33/405 8% 75/280 27% | 0.127Â ns 0.943Â ns |
Kim 2019 [120] | Korea | Serology | 9/44 20% | 1/58 2% | 0.001Â s |
Saleh 2021 [121] | Egypt | Serology | 24/126 19% | 10/120 8% | 0.015Â s |